Ironwood Pharmaceuticals, Inc.
IRWD
$3.73
$0.236.57%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 33.26% | -9.70% | -45.05% | -22.98% | -19.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.26% | -9.70% | -45.05% | -22.98% | -19.47% |
| Cost of Revenue | -24.67% | -23.08% | 6.26% | -32.43% | -9.02% |
| Gross Profit | 61.24% | -3.35% | -72.05% | -4.41% | -23.70% |
| SG&A Expenses | -39.33% | -54.56% | -35.49% | -28.48% | 11.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.70% | -40.36% | -18.49% | -31.69% | 1.24% |
| Operating Income | 202.84% | 66.66% | -192.07% | 1.13% | -47.23% |
| Income Before Tax | 291.62% | 100.37% | -831.59% | -20.97% | -45.61% |
| Income Tax Expenses | 103.60% | -27.93% | -87.79% | -32.29% | -23.68% |
| Earnings from Continuing Operations | 999.29% | 2,844.07% | -798.27% | 229.28% | -73.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 999.29% | 2,844.07% | -798.27% | 307.54% | -76.20% |
| EBIT | 202.84% | 66.66% | -192.07% | 1.13% | -47.23% |
| EBITDA | 198.78% | 65.29% | -184.13% | 1.03% | -46.74% |
| EPS Basic | 983.77% | 2,801.85% | -779.55% | 301.43% | -76.81% |
| Normalized Basic EPS | 297.94% | 76.43% | -421.50% | -5.98% | -60.28% |
| EPS Diluted | 1,047.00% | 1,474.00% | -674.00% | 274.07% | -77.27% |
| Normalized Diluted EPS | 264.16% | 61.36% | -421.50% | -5.98% | -52.52% |
| Average Basic Shares Outstanding | 1.57% | 1.70% | 2.08% | 2.20% | 2.45% |
| Average Diluted Shares Outstanding | 10.94% | 11.21% | 2.08% | 2.20% | -14.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |